STAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
Why it matters: Eli Lilly's investment could accelerate AI-discovered oral therapeutics, potentially bringing new drugs to patients.
- Insilico Medicine secured a deal with Eli Lilly worth $115 million upfront and up to $2.75 billion in biobucks, contingent on milestones.
- Eli Lilly gains rights to develop, manufacture, and commercialize specific preclinical AI-discovered oral therapeutic candidates from Insilico.
- Insilico's pipeline now notes a GLP-1 targeting candidate has been out-licensed to an undisclosed partner, aligning with Zhavoronkov's praise for Lilly's Mounjaro and Zepbound.
- Alex Zhavoronkov, Insilico's CEO, lauded Lilly's AI capabilities and its drug tirzepatide (Mounjaro), stating his desire to develop the 'next one'.
AI drug developer Insilico Medicine has inked a massive commercialization deal with Eli Lilly, potentially worth up to $2.75 billion, granting Lilly rights to develop and commercialize some of Insilico's preclinical AI-discovered oral therapeutic candidates. Insilico CEO Alex Zhavoronkov, a vocal admirer of Lilly's Mounjaro, expressed confidence that Lilly is the ideal partner for these assets, including a GLP-1 targeting candidate that has been out-licensed.
